ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Session » RA – Diagnosis, Manifestations, & Outcomes Poster II: Miscellaneous Aspects of RA (0786–0812)

Date: Sunday, November 7, 2021

Time: 8:30AM-10:30AM

Meeting: ACR Convergence 2021

8:30AM-10:30AM
Abstract Number: 0805
A Real-world Prospective Observational Study of the Effectiveness of Golimumab in Adult Greek Patients with RA, PsA and Axial SpA and Inadequate Response to Initial TNFα Inhibitor Therapy
8:30AM-10:30AM
Abstract Number: 0789
Adipokine Levels and Associations with Achievement of Low Disease Activity in Rheumatoid Arthritis
8:30AM-10:30AM
Abstract Number: 0794
Application of Treat to Target and Impact of Sustained Low Disease Activity or Remission on Function in Rheumatoid Arthritis Patients
8:30AM-10:30AM
Abstract Number: 0812
Are Biologic and Targeted Synthetic Disease Modifying Anti-Rheumatic Drugs Associated with Work Participation Improvement in Early Rheumatoid Arthritis? A Systematic Review and Meta-analysis
8:30AM-10:30AM
Abstract Number: 0787
Association of Hemoglobin Levels and Radiographic Progression in the BRASS Registry
8:30AM-10:30AM
Abstract Number: 0807
Baseline Coping Strategies as Predictors of Outcomes in Patients with Early-onset Rheumatoid Arthritis (RA)
8:30AM-10:30AM
Abstract Number: 0793
Contributing Factors of Good Outcome in Difficult-to-treat Rheumatoid Arthritis: A Multicenter RA Ultrasound Prospective Observational Cohort Study in Japan
8:30AM-10:30AM
Abstract Number: 0806
Coping with Recent-onset Rheumatoid Arthritis (RA): Validation of the Coping with Health Injuries and Problems (CHIP) Questionnaire in a Longitudinal Cohort
8:30AM-10:30AM
Abstract Number: 0786
Diagnostic Utility of FibroScan in Screening for Liver Injury in Patients with Inflammatory Arthritis on Treatment with Methotrexate (MTX)
8:30AM-10:30AM
Abstract Number: 0800
Digital Spatial Profiling Reveals Distinct Synovial Tissue Transcriptomic Signature of Sustained Disease Remission in Rheumatoid Arthritis Patients at Risk of Disease Flare After Treatment Tapering or Discontinuation
8:30AM-10:30AM
Abstract Number: 0801
Early Remission at 6 Months as a Predictor of Longterm Remission in New Onset Rheumatoid Arthritis
8:30AM-10:30AM
Abstract Number: 0802
Infection in Rheumatoid Arthritis Patients Treated with Golimumab
8:30AM-10:30AM
Abstract Number: 0808
Lower Serum MIP-1β Level Is Associated with CsDMARDs Response in Patients with Early Rheumatoid Arthritis
8:30AM-10:30AM
Abstract Number: 0791
Most Rheumatoid Arthritis (RA) Patients from Routine Care Reported in 2008-2021 Have Improved Outcomes vs Earlier Eras, but Most Remain in Moderate/high Disease Activity Rather Than Low Activity/remission: Are New Strategies for Earlier Treatment Needed in Addition to New Agents?
8:30AM-10:30AM
Abstract Number: 0810
Persistent Disease Activity Impairs Work Productivity and Non-work Activity in Recent Onset Rheumatoid Arthritis
8:30AM-10:30AM
Abstract Number: 0797
Psychosocial Wellbeing and Illness Perceptions During the Early Disease Phase Predict Sustained Remission in Rheumatoid Arthritis
8:30AM-10:30AM
Abstract Number: 0788
Red Cell Distribution Width Is Associated with Baseline 25-hydroxyvitamin D Level Before Methotrexate Therapy in Rheumatoid Arthritis
8:30AM-10:30AM
Abstract Number: 0799
Relationships of Rheumatology Care and Patient Experiences to Rheumatoid Arthritis Remission
8:30AM-10:30AM
Abstract Number: 0792
Remission Rates of Patients with Rheumatoid Arthritis in a Tertiary Care
8:30AM-10:30AM
Abstract Number: 0803
Rheumatoid Arthritis Practice Performance (RAPP) Project at 6 Years: Population Medicine (POPMED) Principles and Treat to Target (T2T) Care Yield Dramatic Improvements in Both Outcomes and Access for RA Patients and Productivity for Rheumatologists
8:30AM-10:30AM
Abstract Number: 0798
The Impact of Comorbidities on the Simple Disease Activity Index (SDAI) and Its Components over the First Year of Follow-up – an Analysis from the Canadian Early Arthritis Cohort (CATCH)
8:30AM-10:30AM
Abstract Number: 0809
The Impact of Flares on Clinical and Patient Reported Outcomes in Rheumatoid and Undifferentiated Arthritis Patients
8:30AM-10:30AM
Abstract Number: 0795
Treatment Response and Several Patient-reported Outcomes Are Early Determinants of Future Self-efficacy in Patients with Rheumatoid Arthritis
8:30AM-10:30AM
Abstract Number: 0790
Unraveling Heterogeneity Within ACPA-negative Rheumatoid Arthritis; The Subgroup of Patients with a Strong Clinical and Serological Response to Initiation of DMARD-treatment Favor Disease Resolution
8:30AM-10:30AM
Abstract Number: 0811
Using a Smartphone App to Detect and Characterise Real-Time Patient-Reported Flares in Rheumatoid Arthritis
8:30AM-10:30AM
Abstract Number: 0804
Validation of the 2010 ACR/EULAR Classification Criteria of Rheumatoid Arthritis (RA) in a Nursing-led Triage Clinic
8:30AM-10:30AM
Abstract Number: 0796
Validation of the Simplified Disease Activity Index (SDAI) with a Quick Quantitative C-reactive Protein Assay (SDAI-Q) in Patients with Rheumatoid Arthritis: A National, Multicenter Study

« View all sessions from this meeting

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology